Key statistics
On Tuesday, Innovent Biologics Inc (1801:HKG) closed at 80.05, -26.63% below its 52-week high of 109.10, set on Sep 04, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 82.50 |
|---|---|
| High | 83.50 |
| Low | 79.05 |
| Bid | 80.00 |
| Offer | 80.05 |
| Previous close | 82.60 |
| Average volume | 9.31m |
|---|---|
| Shares outstanding | 1.74bn |
| Free float | 1.62bn |
| P/E (TTM) | 107.30 |
| Market cap | 143.33bn HKD |
| EPS (TTM) | 0.7698 HKD |
Data delayed at least 15 minutes, as of Mar 03 2026 08:08 GMT.
More ▼
- Jaypirca® (Pirtobrutinib) Approved in China for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Innovent Dosed First Participant in Phase 3 Clinical Study of IBI354 (Novel HER2 ADC) for First Line Treatment of HER2-positive Breast Cancer
- Innovent Announces Strategic Collaboration with Lilly to Develop New Medicines Globally in Oncology and Immunology
- Innovent Announces IBI3003 (GPRC5D/BCMA/CD3 Trispecific Antibody) Receives Fast Track Designation from the U.S. FDA for Relapsed or Refractory Multiple Myeloma
- Innovent's Partner Ollin Biosciences Announces Positive Topline Data with Superior Outcomes from a Randomized Head-to-Head Study of IBI324 Compared to Faricimab (Vabysmo®) in Diabetic Macular Edema and Wet Age-Related Macular Degeneration
- China's First Domestic Anti-CTLA-4 Monoclonal Antibody, Innovent's TABOSUN® (Ipilimumab N01 Injection) Received NMPA Approval
- Nature | Two Phase 3 Clinical Results of Mazdutide (GLP-1/GCG Dual Receptor Agonist) in Chinese Adults with Type 2 Diabetes Have Been Back-to-Back Published in Nature
- Mazdutide Demonstrates Significant Weight Loss and Metabolic Benefits in Phase 1b Clinical Trial in Chinese Adolescents with Obesity
- Innovent Announces First Participant Dosed in a Phase 1 Clinical Trial of IBI3011, a Recombinant Anti-Human Interleukin 1 Receptor Accessory Protein Monoclonal Antibody
- Innovent Announces PECONDLE® (Picankibart Injection) Phase 3 Study (CLEAR-2) Meets Endpoints, Delivering Superior Long-Term Management Solution for Moderate-to-Severe Psoriasis
More ▼
